# Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

> **NCT04594772** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Cincinnati** · enrollment: 32 (estimated)

## Conditions studied

- Pancreas Cancer

## Interventions

- **DRUG:** Folfirinox
- **DRUG:** Gemcitabine
- **RADIATION:** radiation therapy
- **PROCEDURE:** Pancreatectomy

## Key facts

- **NCT ID:** NCT04594772
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-17
- **Primary completion:** 2025-06-13
- **Final completion:** 2026-01-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04594772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04594772, "Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04594772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*